← Leaderboards
Daniel Poston
Weill Medical Coll Of Cornell Univ
$191,297
Attributed
$191,297
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $56.8K · FY2021–24$100K$75K$50K$25K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$191,297 · 1
By mechanism
F30$191,297 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Ethel Cesarman$22,572,616
- Jennifer E Totonchy$4,381,010
- Matteo Porotto$18,361,086
- Margaret Leighton McNairy$7,353,073
- Alexander Gitlin$5,765,022
Others in their field
Other Emerging Leaders on “Innate Immune System”
- Aaron Esser-Kahn · University Of Chicago$13,378,548
- Kevin Urdahl · Seattle Children'S Hospital$8,915,198
- Garcia-Sastre Adolfo · Icahn School Of Medicine At Mount Sinai$8,560,974
- Gary Fanger · Rise Therapeutics, Llc$6,698,997
- Daniel Bachovchin · Sloan-Kettering Inst Can Research$6,338,257
- Michael R Ruff · Creative Bio-Peptides, Inc.$6,320,578
Research focus
Innate Immune SystemInfectionAnti-Retroviral AgentsInfectious AgentAnimalsCandidate Disease GeneCellsCofactorCo-ImmunoprecipitationsCrispr/Cas TechnologyBiological ModelsCross-Species TransmissionDesignEmerging Communicable DiseasesEpidemicExperimental StudyFutureGenesGlobal HealthHiv-2Host DefenseHuman Cell LineCrispr ScreenInsight
Grant awards (5)
Elucidating antiviral defenses against diverse immunodeficiency viruses using a novel, high-throughput CRISPR/Cas9 screening method.$35,815
F30 · FY2024 · AI · contact PI
Elucidating antiviral defenses against diverse immunodeficiency viruses using a novel, high-throughput CRISPR/Cas9 screening method.$21,000
F30 · FY2024 · AI · contact PI
Elucidating antiviral defenses against diverse immunodeficiency viruses using a novel, high-throughput CRISPR/Cas9 screening method.$31,694
F30 · FY2023 · AI · contact PI
Elucidating antiviral defenses against diverse immunodeficiency viruses using a novel, high-throughput CRISPR/Cas9 screening method.$51,752
F30 · FY2022 · AI · contact PI
Elucidating antiviral defenses against diverse immunodeficiency viruses using a novel, high-throughput CRISPR/Cas9 screening method.$51,036
F30 · FY2021 · AI · contact PI